A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Sponsors AbbVie
- 12 Sep 2017 Planned End Date changed from 1 Nov 2019 to 8 May 2019.
- 12 Sep 2017 Planned primary completion date changed from 1 Sep 2019 to 8 May 2019.
- 12 Sep 2017 Status changed from recruiting to active, no longer recruiting.